# Data analysis for drug repositioning 

 A comprehensive data mining and analysis effort has been done to present these lists of existing drugs with therapeutic potentials for COVID-19. The analysis was based on different rationales including anti-coronavirus activity, broad-spectrum antiviral activity and antiviral drugs with highly conserved viral target such as RNA dependent RNA polymerase (RDRP). We will constantly update these lists with new discoveries. 


## Data analysis results from previous coronavirus related drug discovery records

A collection of drug candidates with previously published positive coronavirus experimental results.

| Drug name                     | DrugBank ID                                      | Mechanism of action                                          | Experimental activity                                        | Methods                                               | Measurement | Value    | Unit |
| ----------------------------- | ------------------------------------------------ | ------------------------------------------------------------ | ------------------------------------------------------------ | ----------------------------------------------------- | ----------- | -------- | ---- |
| Remdesivir                    | [DB14761](https://www.drugbank.ca/drugs/DB14761) | Nucleobindin-1 (NUCB1) Inhibitors                            | Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO | Viral replication assay                               | IC-50       | 1.00E-08 | M    |
| Emetine                       | [DB13393](https://www.drugbank.ca/drugs/DB13393) | Platelet-Derived Growth Factor (PDGF) Inhibitors;Signal Transduction Modulators;Angiogenesis Inhibitors | Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO | Cytopathicity assay                                   | IC-50       | 1.50E-07 | M    |
| Nafamostat mesilate           | [DB12598](https://www.drugbank.ca/drugs/DB12598) | Tryptase Inhibitors                                          | Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO | Vero cells (TMPRSS2-expressing) transfected with MERS | IC-50       | 1.00E-09 | M    |
| Alisporivir                   | [DB12139](https://www.drugbank.ca/drugs/DB12139) | P-Glycoprotein (MDR-1; ABCB1) Inhibitors;Cyclophilin Inhibitors | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO | RNA assay                                             | IC-50       | 8.00E-07 | M    |
| Niclosamide                   | [DB06803](https://www.drugbank.ca/drugs/DB06803) | Cytochrome P450 CYP1A2 Inhibitors;Quorum Sensing (Pseudomonas aeruginosa) Inhibitors;Neuropeptide Y4 (NPY Y4) Receptor Positive Allosteric Modulators;Autophagy Inducers;Wnt Signaling Inhibitors | Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO | Cytopathicity assay                                   | IC-50       | 1.00E-07 | M    |
| Rupintrivir                   | [DB05102](https://www.drugbank.ca/drugs/DB05102) | HRV 3C Protease Inhibitors                                   | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO | Viral replication assay                               | IC-50       | 3.00E-07 | M    |
| Geldanamycin                  | [DB02424](https://www.drugbank.ca/drugs/DB02424) | Signal Transduction Modulators;Heat Shock Protein 90 (Hsp90) Inhibitors | Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO |                                                       | IC-50       | 9.10E-07 | M    |
| Sinefungin                    | [DB01910](https://www.drugbank.ca/drugs/DB01910) | Coactivator Associated Arginine Methyltransferase 1 (CARM1; PRMT4) Inhibitors;Histone-Lysine N-Methyltransferase SETD7 (SET7/9) Inhibitors;Protein-L-Isoaspartate(D-Aspartate) O-Methyltransferase (PCMT1; PIMT) Inhibitors;Epigenetic Modifier Modulators | Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO |                                                       | IC-50       | 3.83E-07 | M    |
| Mycophenolic acid sodium salt | [DB01024](https://www.drugbank.ca/drugs/DB01024) | Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors    | Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO | Cytopathicity assay                                   | IC-50       | 1.70E-07 | M    |
| Mycophenolate mofetil         | [DB00688](https://www.drugbank.ca/drugs/DB00688) | Hydroxycarboxylic Acid Receptor 2 (HCAR2; NIACR1; GPR109A) Agonists;Signal Transduction Modulators;Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO | Viral replication assay                               | IC-50       | 2.30E-07 | M    |
| Chloroquine                   | [DB00608](https://www.drugbank.ca/drugs/DB00608) |                                                              | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO |                                                       | IC-50       | 8.00E-10 | M    |
| Gemcitabine hydrochloride     | [DB00441](https://www.drugbank.ca/drugs/DB00441) | Ribonucleoside-Diphosphate Reductase Inhibitors;Pyrimidine Antagonists | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO | Cytopathicity assay                                   | IC-50       | 4.40E-07 | M    |
| Promazine                     | [DB00420](https://www.drugbank.ca/drugs/DB00420) | Signal Transduction Modulators;Dopamine Receptor Antagonists | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO | Cytopathicity assay                                   | MIC         | 1.00E-07 | M    |
| Azithromycin                  | [DB00207](https://www.drugbank.ca/drugs/DB00207) | Nonsense Mutation Suppressors;50S Ribosomal Protein Inhibitors | Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO | Luciferine/luciferase assay                           | IC-50       | 1.00E-07 | M    |
| cyclosporin                   | [DB00091](https://www.drugbank.ca/drugs/DB00091) | Cyclophilin Inhibitors;Mitochondrial Permeability Transition (MPT) Inhibitors | Coronavirus acute respiratory syndrome remission/reduction, IN VITRO | RNA assay                                             | IC-50       | 8.00E-07 | M    |

## Broad-spectrum antiviral data analysis results

Based on in vitro viral infection assay results (EC50<=1uM) and clinical data (in vivo active) we have identified 51 molecules against at least 5 virus species and 10 molecules against at least 10 virus species. The details of the top candidates are shown below:

|  ï»¿Drug name  | Drug ID  | Number of virus speices  | Virus species list  | Discovered MOA  |
| ---- | --- | --- | --- | --- |
|  Tenofovir  | [DB14126](https://www.drugbank.ca/drugs/DB14126)  | 15  | FLUAV;HCV;HBV;HSV;HSV-2;HIV-1;HIV-2;ADV;DENV;RSV;CMV;VZV;Parainfluenza virus;Rhinovirus;Xenotropic murine leukemia virus-related virus  | Nucleotide reverse transcriptase inhibitor  |
|  Nitazoxanide  | [DB00507](https://www.drugbank.ca/drugs/DB00507)  | 13  | MERS-CoV;ZIKV;FLUAV;FLUBV;HBV;HCV;HIV-1;DENV;RSV;ADV;NoV;RuV;JEV  | Hemagglutinin inhibitor  |
|  Mycophenolic acid  | [DB01024](https://www.drugbank.ca/drugs/DB01024)  | 13  | MERS-CoV;CoV;ZIKV;DENV;HCV;FLUAV;FLUBV;WNV;RSV;BKV;Avian flu;Filovirus;Parainfluenza virus  | Dehydrogenase  |
|  Brincidofovir  | [DB12151](https://www.drugbank.ca/drugs/DB12151)  | 13  | EBOV;CMV;HSV;VZV;BKV;ADV;EBV;HTLV-1;HPV;HSV-1;HSV-6;VACV;JC polyomavirus  | DNA polymerase Inhibitor  |
|  Ribavirin  | [DB00811](https://www.drugbank.ca/drugs/DB00811)  | 11  | FLU;FLUAV;FLUBV;HCV;RSV;EV;HSV;HEV;LASV;Avian flu;Parainfluenza virus  | Inosine monophosphate dehydrogenase inhibitor; RNA-dependent RNA polymerase inhibitor  |
|    | [CID:5480370](https://pubchem.ncbi.nlm.nih.gov/compound/5480370)  | 11  | FLUAV;DENV;HBV;HCV;HSV;ADV;RSV;CMV;VZV;Rhinovirus;Parainfluenza virus  |   |
|  Remdesivir  | [DB14761](https://www.drugbank.ca/drugs/DB14761)  | 10  | CoV;SARS-CoV;MERS-CoV;2019nCoV;EBOV;ZIKV;MARV;HCV;RSV;Filovirus  | RNA polymerase inhibitor  |
|  Tilorone  | [DB09070](https://www.drugbank.ca/drugs/DB09070)  | 10  | MERS-CoV;EBOV;HBV;HCV;CHIKV;CMV;HAV;HSV-1;MARV;WNV   | Interferon inducers  |
|  Cidofovir  | [DB00369](https://www.drugbank.ca/drugs/DB00369)  | 10  | HPV;CMV;HSV;EBV;VZV;ADV;BKV;HSV-1;HSV-2;JC polyomavirus  | DNA polymerase Inhibitor  |
|    | [CID:71761402](https://pubchem.ncbi.nlm.nih.gov/compound/71761402)  | 10  | SARS-CoV;FLUAV;FLUBV;DENV;ADV;RSV;WNV;Filovirus;Rhinovirus;Parainfluenza virus  |   |


  <details>
      <summary> Top 51 list </summary>

| ID | name | Number of virus species | Virus species list | Discovered MOA |
|-----------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|-------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| [DB14126](https://www.drugbank.ca/drugs/DB14126) | Tenofovir | 15 | FLUAV;HCV;HBV;HSV;ADV;DENV;Parainfluenza virus;RSV;Rhinovirus;CMV;VZV;Xenotropic murine leukemia virus-related virus;HIV-2;HIV-1;HSV 2 | Reverse Transcriptase/Ribonuclease H (HIV-1) Inhibitors;Reverse Transcriptase/Ribonuclease H (Viral) Inhibitors |
| [DB12151](https://www.drugbank.ca/drugs/DB12151) | Brincidofovir | 13 | EBOV;CMV;HSV;VZV;BKV;ADV;JC polyomavirus;EBV;HTLV-1;HPV;HSV 1;VACV;HSV-6 | DNA Polymerase Inhibitors |
| [DB00507](https://www.drugbank.ca/drugs/DB00507) | Nitazoxanide | 13 | FLUAV;FLUBV;HBV;HCV;DENV;RSV;ADV;NoV;RuV;HIV-1;JEV;MERS-CoV;ZIKV | Signal Transduction Modulators;Viral Maturation Inhibitors;Pyruvate Synthase (Pyruvate-Ferredoxin Oxidoreductase; PFOR) (Protozoal) Inhibitors;Myc Proto-Oncogene Protein (c-Myc) Inhibitors;Hemagglutinin (HA) (Viral) Inhibitors;Protein Disulfide-Isomerase A3 (PDIA3) Inhibitors;Viral Fusion Inhibitors;Pyruvate Synthase (Pyruvate-Ferredoxin Oxidoreductase; PFOR) (Bacterial) Inhibitors |
| [DB01024](https://www.drugbank.ca/drugs/DB01024) | Mycophenolic acid | 13 | Avian flu;HCV;FLUBV;Filovirus;FLUAV;MERS-CoV;CoV;WNV ;DENV;ZIKV;RSV;Parainfluenza virus;BKV | Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors |
| [DB09299](https://www.drugbank.ca/drugs/DB09299) | Tenofovir alafenamide fumarate | 11 | FLUAV;HCV;HBV;HSV;Parainfluenza virus;ADV;DENV;RSV;Rhinovirus;CMV;VZV | Reverse Transcriptase/Ribonuclease H (HIV-1) Inhibitors;Reverse Transcriptase/Ribonuclease H (Viral) Inhibitors |
| [DB00811](https://www.drugbank.ca/drugs/DB00811) | Ribavirin | 11 | Avian flu;FLUBV;HCV;FLU;FLUAV;RSV;EV;Parainfluenza virus;HSV;HEV;LASV | Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors;Equilibrative Nucleoside Transporter ENT1 Inhibitors |
| [CID: 71761401](https://pubchem.ncbi.nlm.nih.gov/compound/71761401) | [(2R,3R,4S,5S)-5-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-3,4-dihydroxypyrrolidin-2-yl]methyl (2S)-2-amino-3-methylbutanoate | 10 | Filovirus;SARS-CoV;FLUAV;FLUBV;Parainfluenza virus;DENV;ADV;Rhinovirus;RSV;WNV | RNA Polymerase Inhibitors |
| [DB14761](https://www.drugbank.ca/drugs/DB14761) | Remdesivir | 10 | MERS-CoV;Filovirus;EBOV;CoV;SARS-CoV;MARV;HCV;RSV;ZIKV;2019nCoV | Nucleobindin-1 (NUCB1) Inhibitors |
| [CID: 33958](https://pubchem.ncbi.nlm.nih.gov/compound/33958) | Tilorone hydrochloride | 10 | CHIKV;CMV;EBOV;HAV;HBV;HCV;HSV 1;MARV;MERS-CoV;WNV | Signal Transduction Modulators;Interferon Inducers |
| [DB00369](https://www.drugbank.ca/drugs/DB00369) | Cidofovir | 10 | CMV;HSV;EBV;VZV;JC polyomavirus;ADV;BKV;HSV 1;HSV 2;HPV | DNA Polymerase Inhibitors |
| [CID: 49787172 ](https://pubchem.ncbi.nlm.nih.gov/compound/49787172 ) | PTC299 | 9 | FLUAV;HCV;PV;Parainfluenza virus;WNV ;RSV;ADV;HSV;DENV | Signal Transduction Modulators;Vascular Endothelial Growth Factor (VEGF) Inhibitors;Angiogenesis Inhibitors |
| [CID: 67986080](https://pubchem.ncbi.nlm.nih.gov/compound/67986080) | (4-chlorophenyl) (1S)-6-chloro-1-[4-[(3S)-3,4-dihydroxybutoxy]phenyl]-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate | 8 | FLUAV;PV;ADV;Parainfluenza virus;WNV ;RSV;HSV;DENV | VEGF Expression Inhibitors;Angiogenesis Inhibitors |
| [DB12466](https://www.drugbank.ca/drugs/DB12466) | Favipiravir | 8 | FLUAV;FLUBV;FLUCV;2019nCoV;CCHFV;CHIKV;EBOV;MARV | Viral Polymerase Inhibitors |
| [CID: 10027278](https://pubchem.ncbi.nlm.nih.gov/compound/10027278) | OSU-03012 | 8 | Filovirus;FLUAV;MARV;EBOV;HCV;ZIKV;HSV;DENV | Acetyl-Coenzyme A Synthetase (Fungal) Inhibitors;Signal Transduction Modulators;Heat Shock Protein 90 (Hsp90) Inhibitors;Phosphoinositide Dependent Kinase (PDK) 1 Inhibitors;Serine/Threonine-Protein Kinase PKH2 (Fungal) Inhibitors;Heat Shock Protein 70 (Hsp70) Inhibitors;Apoptosis Inducers |
| [DB00577](https://www.drugbank.ca/drugs/DB00577) | valaciclovir | 7 | HSV;CMV;EBV;HBV;HSV 1;HSV 2;VZV | DNA Polymerase Inhibitors; DNA Directed DNA Polymerase Inhibitors |
| [DB00608](https://www.drugbank.ca/drugs/DB00608) | Chloroquine | 7 | CoV;DENV;HIV-1;CHIKV;EBOV;FLUAV;HCV |  |
| [DB00091](https://www.drugbank.ca/drugs/DB00091) | Ciclosporin | 7 | HCV;FLUBV;CoV;HBV;FLUAV;HIV-1;CMV | Cyclophilin D Inhibitors;Signal Transduction Modulators;Serine/Threonine-Protein Phosphatase 2B (PPP3CC; PP2Bgamma; Calcineurin) Inhibitors;INS Expression Inhibitors |
| [CID: 11787114](https://pubchem.ncbi.nlm.nih.gov/compound/11787114) | Silvestrol | 7 | CoV;HCV;MERS-CoV;EBOV;EBV;HPV;Rhinovirus | Eukaryotic Initiation Factor 4A (eIF4A) Inhibitors;Apoptosis Inducers |
| [DB00877](https://www.drugbank.ca/drugs/DB00877) | Sirolimus | 7 | CMV;HCV;BKV;FLUAV;HIV-1;KSHV;RVFV | CCR5 Expression Inhibitors;Signal Transduction Modulators;Proteasome Inhibitors;Drugs Targeting B-Lymphocyte Antigen CD19;Mammalian Target of Rapamycin (mTOR; FRAP1) Inhibitors |
| [DB08826](https://www.drugbank.ca/drugs/DB08826) | deferiprone extended-release | 7 | CMV;BKV;VZV;JC polyomavirus;HSV;ADV;EBV | Chelating Agents; Cytochrome P450 CYP4F2 Inhibitors; Iron Absorption Inhibitors; Lipoxygenase 5 Inhibitors |
| [CID: 136896143](https://pubchem.ncbi.nlm.nih.gov/compound/136896143) | NITD-008 | 6 | Filovirus;HCV;EV;DENV;ZIKV;WNV | RNA-Directed RNA Polymerase (NS5) (Dengue Virus) Inhibitors |
| [DB00787](https://www.drugbank.ca/drugs/DB00787) | Aciclovir | 6 | HBV;HSV;VZV;EBV;HSV 1;HSV 2 | DNA Polymerase Inhibitors |
| [CID: 86263464](https://pubchem.ncbi.nlm.nih.gov/compound/86263464) | KIN-269 | 6 | FLUAV;CoV;FLUBV;RSV;WNV ;DENV | Interferon Regulatory Factor 3 (IRF-3) Activators |
| [DB12116](https://www.drugbank.ca/drugs/DB12116) | (-)-Epigallocatechin gallate | 6 | ADV;HCV;CMV;HSV;FLUAV;ZIKV | SGLT-1 Inhibitors;Tumor NADH Oxidase (tNOX) Inhibitors;Immune Checkpoint Inhibitors;Viral Attachment Inhibitors;Aromatase Inhibitors;beta-Amyloid (Abeta) Aggregation Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;Efflux Pump (Bacterial) Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Fatty Acid Synthase (FAS) Inhibitors;Signal Transduction Modulators;Dual-Specificity Tyrosine-(Y)-Phosphorylation Regulated Kinase 1A (DYRK1A) Inhibitors;Proteasome Inhibitors;Indoleamine 2,3-dioxygenase 1 (IDO1; IDO) Inhibitors;beta-Amyloid (Abeta) Protein Neurotoxicity Inhibitors;AP-1 Transcription Factor Complex Inhibitors;Glycoprotein 120 (gp120) Inhibitors;PDGFR Family Inhibitors;beta-Secretase (BACE) Inhibitors;Prolyl Endopeptidase (prolyl oligopeptidase; POP) Inhibitors;Antioxidants;Telomerase Reverse Transcriptase (TERT) Inhibitors;Antiamyloidogenic Agents;Angiogenesis Inhibitors;Serine Protease NS3 (HCV) Inhibitors;Wnt Signaling Inhibitors |
| [DB01268](https://www.drugbank.ca/drugs/DB01268) | Sunitinib malate | 6 | HCV;EBOV;RSV;DENV;ZIKV;WNV | Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret (RET; CDHF12; PTC) Inhibitors;VEGFR-3 (FLT4) Inhibitors;VEGFR-2 (FLK-1/KDR) Inhibitors;Signal Transduction Modulators;PDGFRbeta Inhibitors;KIT (C-KIT) Inhibitors;Leucine-Rich Repeat Kinase 2 (LRRK2; Dardarin) Inhibitors;CSF1R (c-FMS) Inhibitors;Flt3 (FLK2/STK1) Inhibitors;VEGFR-1 (Flt-1) Inhibitors;Angiogenesis Inhibitors |
| [DB00709](https://www.drugbank.ca/drugs/DB00709) | Lamivudine | 6 | HBV;HCV;EV;EBV;HIV-1;HIV-2 | DNA Polymerase Inhibitors;Reverse Transcriptase/Ribonuclease H (HIV-1) Inhibitors;Reverse Transcriptase/Ribonuclease H (Viral) Inhibitors |
| [DB00207](https://www.drugbank.ca/drugs/DB00207) | Azithromycin | 6 | EBOV;SARS-CoV;MERS-CoV;RSV;FLUAV;HIV-1 | Nonsense Mutation Suppressors;50S Ribosomal Protein Inhibitors |
| [CID: 197020](https://pubchem.ncbi.nlm.nih.gov/compound/197020) | NHC | 6 | HCV;Avian flu;SARS-CoV;FLUBV;FLUAV;RSV |  |
| [CID: 66552950](https://pubchem.ncbi.nlm.nih.gov/compound/66552950) | 3-Bromo-3-deazaneplanocin | 6 | FLUAV;FLUBV;Filovirus;EBV;HSV;Parainfluenza virus |  |
| [DB01004](https://www.drugbank.ca/drugs/DB01004) | Ganciclovir | 6 | CoV;HSV;CMV;VZV;EBV;ADV | DNA Polymerase Inhibitors |
| [DB00495](https://www.drugbank.ca/drugs/DB00495) | Zidovudine | 6 | Avian flu;Xenotropic murine leukemia virus-related virus;EBV;EV;HSV;HTLV-1 | P-Glycoprotein (MDR-1; ABCB1) Inhibitors;Breast Cancer-Resistant Protein (BCRP; ABCG2) Inhibitors;Reverse Transcriptase/Ribonuclease H (HIV-1) Inhibitors |
| [CID: 135565845](https://pubchem.ncbi.nlm.nih.gov/compound/135565845) | ABI-1968 | 6 | HBV;HSV;CMV;BKV;HPV;JC polyomavirus |  |
| [CID: 52914323](https://pubchem.ncbi.nlm.nih.gov/compound/52914323) | aUY-11 | 5 | FLU;HCV;FLUAV;CMV;HSV | Viral Fusion Inhibitors |
| [DB02424](https://www.drugbank.ca/drugs/DB02424) | Geldanamycin | 5 | SARS-CoV;HCV;HBV;CMV;HSV | Signal Transduction Modulators;Heat Shock Protein 90 (Hsp90) Inhibitors |
| [CID: 10031478 ](https://pubchem.ncbi.nlm.nih.gov/compound/10031478 ) | ODE-(S)HPMPA | 5 | HCV;HBV;HSV;ADV;CMV |  |
| [CID: 15958371](https://pubchem.ncbi.nlm.nih.gov/compound/15958371) | HDP-PME-cPr-DAP | 5 | HBV;EBV;CMV;VZV;HSV |  |
| [CID: 46866178](https://pubchem.ncbi.nlm.nih.gov/compound/46866178) | Di-O-decanoylcurcumin | 5 | FLUAV;FLUBV;HSV;RSV;Parainfluenza virus |  |
| [CID: 46933910](https://pubchem.ncbi.nlm.nih.gov/compound/46933910) | [(2S,3S,5R)-3-(dimethylamino)-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl (2S)-2-amino-3-phenylpropanoate | 5 | FLUAV;FLUBV;RSV;HSV;Parainfluenza virus |  |
| [DB00530](https://www.drugbank.ca/drugs/DB00530) | Erlotinib hydrochloride | 5 | Filovirus;HCV;RSV;EBOV;DENV | Signal Transduction Modulators;EGFR (HER1; erbB1) Inhibitors |
| [CID: 53362039](https://pubchem.ncbi.nlm.nih.gov/compound/53362039) | NITD-982 | 5 | FLUAV;FLUBV;HCV;DENV;RSV | Dihydroorotate Dehydrogenase (DHODH) Inhibitors |
| [CID: 46866177](https://pubchem.ncbi.nlm.nih.gov/compound/46866177) | Di-O-tryptophanylphenylalaninecurcumin | 5 | FLUAV;FLUBV;RSV;HSV;Parainfluenza virus |  |
| [CID: 72378](https://pubchem.ncbi.nlm.nih.gov/compound/72378) | Lycorine | 5 | CoV;HCV;SARS-CoV;DENV;WNV |  |
| [CID: 56854033](https://pubchem.ncbi.nlm.nih.gov/compound/56854033) | (2S,4R)-4-(1H-Benzimidazol-2-ylsulfanyl)-1-(9H-fluoren-2-ylmethyl)-N-(2-methoxyethyl)pyrrolidine-2-carboxamide | 5 | FLUBV;HCV;FLUAV;DENV;RSV |  |
| [DB12531](https://www.drugbank.ca/drugs/DB12531) | Lobucavir | 5 | HBV;HSV;VZV;CMV;HIV-1 | DNA Polymerase Inhibitors |
| [CID: 135934890](https://pubchem.ncbi.nlm.nih.gov/compound/135934890) | C4-Ethyl-O-gamma-folylcurcumin | 5 | FLUAV;FLUBV;RSV;HSV;Parainfluenza virus |  |
| [DB01601](https://www.drugbank.ca/drugs/DB01601) | Lopinavir | 5 | HIV-1;HIV-2;MERS-CoV;2019nCoV;ZIKV | HIV Protease Inhibitors |
| [DB00441](https://www.drugbank.ca/drugs/DB00441) | Gemcitabine hydrochloride | 5 | FLUAV;CoV;HCV;ZIKV;HSV | Ribonucleoside-Diphosphate Reductase Inhibitors;Pyrimidine Antagonists |
| [CID: 23519651](https://pubchem.ncbi.nlm.nih.gov/compound/23519651) | 4-amino-1-[(2R,4R,5R)-5-azido-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one | 5 | Filovirus;EBOV;HCV;RSV;Parainfluenza virus | RNA-Directed RNA Polymerase (NS5B) (HCV) Inhibitors;RNA-Directed RNA Polymerase (Respiratory Syncytial Virus) Inhibitors |
| [CID: 72253](https://pubchem.ncbi.nlm.nih.gov/compound/72253) | HPMPA-(S) | 5 | VZV;HSV;EBV;CMV;ADV |  |
| [DB00198](https://www.drugbank.ca/drugs/DB00198) | Oseltamivir phosphate | 5 | FLUAV;FLU;Avian flu;FLUBV;Parainfluenza virus | Neuraminidase (Sialidase) (Influenza Virus) Inhibitors |
| [CID: 71730493](https://pubchem.ncbi.nlm.nih.gov/compound/71730493) | LDC-4297 | 5 | FLUAV;CMV;HSV;VZV;ADV | Signal Transduction Modulators;Cyclin-Dependent Kinase 7 (CDK7) Inhibitors;Apoptosis Inducers |

</details>

## Data analysis results from previous other antiviral drug discovery records

A collection of drug candidates in pipelines or marketed for different antiviral indications. All candidates have at least completed Phase I studies. However, not all have in vitro anti-coronavirus or anti-2019nCoV evidence yet, further studies using 2019-nCoV specific assays are required to evaluate their anti-2019nCoV potential. 


### 1. Antiviral candidates selected from viral replication assay

| Drug name               | DrugBank ID                                      | Clinical Information                                         | Mechanism of action                                          | Experimental activity                                        | Method                  | Measurement | Value    | Unit |
| ----------------------- | ------------------------------------------------ | ------------------------------------------------------------ | ------------------------------------------------------------ | ------------------------------------------------------------ | ----------------------- | ----------- | -------- | ---- |
| Deferiprone             | [DB08826](https://www.drugbank.ca/drugs/DB08826) | 1. Phase 4 completed  for acute iron intoxication <br/>2. Phase 4 completed for Hepatic impairment <br/>3.  Phase 4 completed for impaired kidney function <br/>4. Phase 4 completed for  Beta-Thalassemia <br/>5. Phase 4 completed for hemosiderosis <br/>6. Phase 4  completed for Prolonged QT Interval <br/>7. Phase III completed for Parkinson's  disease; <br/>Marketed for iron toxicity | Chelating Agents;Cytochrome P450 CYP4F2 Inhibitors           | Infection, BK polyomavirus remission/reduction, IN VITRO     | Viral replication assay | IC-50       | 3.50E-09 | M    |
| Raltegravir potassium   | [DB06817](https://www.drugbank.ca/drugs/DB06817) | Phase 4 completed  for HIV <br/>Marketed for Anti-Retroviral HIV | HIV Integrase Inhibitors                                     | Infection, xenotropic murine leukemia virus-related virus remission/reduction, IN VITRO | Viral replication assay | IC-50       | 5.00E-9  | M    |
| Verdinexor              | [DB12207](https://www.drugbank.ca/drugs/DB12207) | Phase 1 completed  for basic science on health volunteers    | Exportin-1 (CRM1, XPO1) Receptor Antagonists;Signal Transduction Modulators | Infection, JC polyomavirus remission/reduction, IN VITRO     | Viral replication assay | IC-50       | 7.50E-09 | M    |
| Brincidofovir           | [DB12151](https://www.drugbank.ca/drugs/DB12151) | Phase 3 completed  for adenovirus infections                 | DNA Polymerase Inhibitors                                    | Infection, JC polyomavirus remission/reduction, IN VITRO     | Viral replication assay | IC-50       | 2.00E-8  | M    |
| Remdesivir              | [DB14761](https://www.drugbank.ca/drugs/DB14761) | 1. Phase III for  Ebola <br>2. Phase III for nCoV            | Nucleobindin-1 (NUCB1) Inhibitors                            | Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO | Viral replication assay | IC-50       | 2.50E-8  | M    |
| Verdinexor              | [DB12207](https://www.drugbank.ca/drugs/DB12207) | Phase I completed  for basic science experiments on healthy volunteers | Exportin-1 (CRM1, XPO1) Receptor Antagonists;Signal Transduction Modulators | Infection, adenovirus remission/reduction, IN VITRO          | Viral replication assay | IC-50       | 3.00E-8  | M    |
| Cidofovir               | [DB00369](https://www.drugbank.ca/drugs/DB00369) | Phase 4 completed  for cytomegalovirus <br/>Marketed for CMV in AIDS patients | DNA Polymerase Inhibitors                                    | Infection, cytomegalovirus remission/reduction, IN VITRO     | Viral replication assay | IC-99       | 6.00E-8  | M    |
| Alvocidib hydrochloride | [DB03496](https://www.drugbank.ca/drugs/DB03496) | 1. Phase II  completed for sarcomas <br>2. Phase II completed for renal cancers; <br>3. Phase II  completed for melanoma <br>4. Phase II completed for other cancers including:  myeloma, carcinoma, esophageal, endometrial, leukaemia, etc. | Cyclin-Dependent Kinase 1 (CDK1) Inhibitors;Signal Transduction Modulators;Cyclin-Dependent Kinase 6 (CDK6) Inhibitors;CDK9/Cyclin T1 Inhibitors;Baculoviral IAP Repeat-Containing Protein 5 (BIRC5; Survivin) Inhibitors;Apoptosis Inducers;Cyclin-Dependent Kinase 7 (CDK7) Inhibitors;Cyclin-Dependent Kinase 2 (CDK2) Inhibitors;Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 Inhibitors;Cyclin-Dependent Kinase 4 (CDK4) Inhibitors;X-Chromosome-Linked Inhibitor of Apoptosis Protein (XIAP) Inhibitors;Apoptosis Regulator Bcl-2 Inhibitors | Infection, herpes virus remission/reduction, IN VITRO        | Viral replication assay | IC-50       | 1.00E-07 | M    |
| Ganciclovir             | [DB01004](https://www.drugbank.ca/drugs/DB01004) | 1. Phase 4 active  for viral pneumonia <br>2. Phase 4 completed for DNA virus infections <br>3. Phase 4  completed for CMV <br>4. Phase 4 completed for viral sepsis | DNA Polymerase Inhibitors                                    | Infection, herpes simplex virus remission/reduction, IN VITRO | Viral replication assay | IC-50       | 1.00E-8  | M    |

---

### 2. Top antiviral candidates with RDRP inhibition MOA selected from different assays

| Drug name      | DrugBank ID                                      | Mechanism of action                                          | Experimental activity                                        | Measurement | Value    | Unit |
| -------------- | ------------------------------------------------ | ------------------------------------------------------------ | ------------------------------------------------------------ | ----------- | -------- | ---- |
| Beclabuvir     | [DB12225](https://www.drugbank.ca/drugs/DB12225) | RNA-Dependent RNA Polymerase (NS5B) (HCV) Inhibitors         | Hepatitis C (HCV) remission/reduction, IN VITRO              | IC-50       | 3.00E-09 | M    |
| Remdesivir     | [DB14761](https://www.drugbank.ca/drugs/DB14761) | RNA-Dependent RNA Polymerase Inhibitor                       | Ebola virus disease remission/reduction, IN VITRO            | IC-50       | 1.00E-08 | M    |
| Valopicitabine | [DB13920](https://www.drugbank.ca/drugs/DB13920) | RNA-Dependent RNA Polymerase (NS5B) (HCV) Inhibitors         | Hepatitis C (HCV) remission/reduction, IN VITRO              | IC-50       | 9.00E-08 | M    |
| Mericitabine   | [DB12045](https://www.drugbank.ca/drugs/DB12045) | RNA-Dependent RNA Polymerase (NS5B) (HCV) Inhibitors         | Hepatitis C (HCV) remission/reduction, IN VITRO              | IC-50       | 1.30E-07 | M    |
| Lumicitabine   | [DB14808](https://www.drugbank.ca/drugs/DB14808) | RNA-Dependent RNA Polymerase (Respiratory Syncytial Virus) Inhibitors | Infection, respiratory syncytial virus (RSV) remission/reduction, IN VITRO | IC-50       | 2.60E-07 | M    |
| Sofosbuvir     | [DB08934](https://www.drugbank.ca/drugs/DB08934) | RNA-Dependent RNA Polymerase (NS5B) (HCV) Inhibitors         | Infection, dengue virus remission/reduction, IN VITRO        | IC-90       | 4.00E-07 | M    |
| Adafosbuvir    | [DB14906](https://www.drugbank.ca/drugs/DB14906) | RNA-Dependent RNA Polymerase (NS5B) (HCV) Inhibitors         | Infection, dengue virus remission/reduction, IN VITRO        | IC-50       | 1.10E-06 | M    |
| Balapiravir hydrochloride | [DB12283](https://www.drugbank.ca/drugs/DB12283) | RNA-Dependent RNA Polymerase (NS5B) (HCV) Inhibitors          | Infection, dengue virus remission/reduction, IN VITRO        | IC-50     |1.9E-06  | M    |
| Galidesivir | [DB11676](https://www.drugbank.ca/drugs/DB11676) |RNA-Dependent RNA Polymerase Inhibitors|  Infection, Zika virus remission/reduction, IN VITRO                             | IC-50     | 2.96E-06 | M    |
| Favipiravir   | [DB12466](https://www.drugbank.ca/drugs/DB12466) |RNA-Dependent RNA Polymerase Inhibitors| Infection, rabies virus remission/reduction, IN VITRO                             | MIC       |  4.0E-06   | M    |


*Compounds selected based on best IC-50 measurement from respective assays.

